Business
Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
AURORA, ON, June 11 /CNW/ - Helix BioPharma Corp. (TSX, FSE: "HBP"), a biopharmaceutical company ...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nAURORA, ON, June 11 /CNW/ - Helix BioPharma Corp. (TSX, FSE: "HBP"), a\nbiopharmaceutical company specializing in the field of cancer therapy, today\nannounced its product development progress, quarterly highlights and financial\nresults for the three and nine month periods ended April 30, 2008.\n\n\n"During the quarter, we made significant advancements in the development\nof our lead clinical compounds," said John Docherty, President of Helix\nBiopharma. "We are currently developing plans for Topical Interferon to enter\nexpanded Phase II/III clinical trials and we are anticipating L-DOS47 entering\nthe clinic in a Phase I study."\n\n\nHIGHLIGHTS\n\nThe Company's highlights for the quarter included the following events:\n\nClinical Development\n\n- Helix met with the German Federal Institute for Drugs and Medical\n Devices (BfArM) as a preliminiary step toward filing its CTA for a\n planned large, randomized, placebo-controlled, double-blind Phase III\n European clinical trial of Topical Interferon Alpha-2b in patients\n with low-grade cervical lesions ("LSIL");\n\n- Helix received approval from the Swedish Medical Products Agency for\n a clinical protocol amendment to expand its Topical Interferon\n Alpha-2b AGW clinical trial to sites in Germany;\n\n- The Prominent German dermatologist, Professor Dr. med. Eggert\n Stockfleth of the Department of Dermatology, Skin Cancer Center\n Charite, Universitätsmedizin Berlin, was engaged by Helix to act as\n the German co-ordinating investigator for the expanded AGW clinical\n trial in Germany;\n\nGMP Manufacturing\n\n- Contract Pharmaceuticals Limited Niagara was engaged by Helix to\n further scale-up the Topical Interferon Alpha-2b GMP production\n process in anticipation of conducting clinical trials in the U.S. and\n Europe in patients with LSIL;\n\n- Signed a second, more definitive agreement with BioVectra dcl to\n further scale-up the GMP production of the L-DOS47 active drug\n substance for purposes of producing clinical trial batches.\n\nInvestor and Media Relations\n\n- Appointed New York based Russo Partners as both investor and media\n relations group.\n\n\nRESULTS FROM OPERATIONS\n\n\nThree and nine month periods ended April 30, 2008 compared to the same\n\n\nperiod in the previous year\n\n\nLoss for the period\n\n\nThe C...